Related Experiment Video
Updated: Jun 24, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
Richard M Nixon1, Anthony O'Hagan, Jeremy Oakley
1MRC Biostatistics Unit, Cambridge, UK.
Pharmaceutical Statistics
|April 3, 2009
Summary
This study introduces a model to optimize rheumatoid arthritis drug development decisions. It simulates clinical trials to predict the probability of successful drug registration, guiding key strategic choices.
Area of Science:
- Pharmacoeconomics and Health Economics
- Clinical Trial Design and Simulation
- Rheumatology Drug Development
Background:
- Drug development involves complex decisions under uncertainty, significantly impacting registration success.
- The Rheumatoid Arthritis Drug Development Model (RADDM) was created to aid strategic decision-making for new rheumatoid arthritis treatments.
Purpose of the Study:
- To develop and apply a simulation model for optimizing clinical development programs for rheumatoid arthritis drugs.
- To evaluate the impact of various trial design parameters on the probability of successful drug registration.
Main Methods:
- Utilized Bayesian clinical trial simulation to model Phase 2b and 3 trials.
- Incorporated data on new drug efficacy, existing treatments, and expert safety criteria.
- Assessed parameters including sample size, dosage, comparator choice, and outcome measures (ACR20, ACR50).
Main Results:
- The model evaluates diverse development program scenarios, considering factors like patient population and trial duration.
- Probabilities of successful drug registration varied significantly based on trial design.
- For a new treatment, registration success probabilities ranged from 0.044-0.142 (ACR20) and 0.057-0.213 (ACR50).
Conclusions:
- The Rheumatoid Arthritis Drug Development Model provides a realistic assessment of trial outcomes for informed decision-making.
- Optimizing clinical trial design is crucial for maximizing the likelihood of successful drug registration in rheumatoid arthritis.
- The model demonstrates the sensitivity of registration success to specific design choices in clinical development programs.
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.